You have returned to the top of the page.
Women with breast cancer often have additional physical and psychological stresses to cope with during their treatment, many of which are preventable. For example, two thirds of those who are hospitalised with advanced metastatic breast cancer will have a delirium episode at some point during a stay in hospital.
Delirium is a serious medical condition affecting the brain, which results in confused thinking and reduced awareness of environment. It also impacts the ability to communicate at a critical time when being mentally aware and interacting with loved ones is crucial for quality of life.
Women with advanced metastatic breast cancer are at higher risk of delirium due to medical problems such as changes in blood levels of calcium or oxygen, infections, and the side effects of their medications. Each year it is estimated that at least 2000 women with advanced breast cancer experienced delirium before their death during a hospital stay. Delirium is reversible in only half of cases and there is no medication to effectively treat its symptoms.
Delirium is one of the most significant medical complications for those in the final stages of breast cancer. It has serious adverse consequences: it is highly distressing to experience for the person themselves and to witness as a family member, it increases the risk of complication in hospital such as falls, reduced independence and function and cognitive capacity, and is associated with longer hospital stays, higher health care costs and a high mortality rate.
The good news is that delirium is preventable in many cases and recent research has shown that incidences of delirium in older hospitalised adults can be reduced by up to 50 per cent. Additional data is needed specifically for the women with advanced metastatic breast cancer which takes into account other factors such as fatigue and/or limited mobility.
NBCF-funded Professor Meera Agar and her team will run a trial to collect data on the benefits of methods to avoid delirium episodes. These methods include ensuring they get enough sleep, enhancing physical function, maximising hydration and nutrition and making sure patients are not isolated from sounds and senses which help to keep them grounded.
Professor Agarâ€™s research program aims to reduce the incidence of delirium in women with advanced metastatic breast cancer by 50 per cent, a change which would mean a significant improvement to their quality and length of life.
Research has improved the success rate of breast cancer to 90 per cent, but for women with metastatic breast cancer (when the cancer has spread beyond the breast) modern treatments are only able to prolong life, not stop the cancer progressing.
Targeted therapies are a new class of medicines that have improved the survival and quality of life of breast cancer patients. Targeted therapies are among the last treatment options for metastatic breast cancer patients in the very advanced stages of the disease, and while some patients experience substantial benefit from these medicines, unfortunately, many others either do not respond or experience severe toxicity.
In this project, Dr Ashley Hopkins will use advanced mathematical techniques aiming to identify predictors of good and bad outcomes to targeted therapies usedâ€¨in metastatic breast cancer. Dr Hopkins will analyse data that has been collected across a series of clinical trials on targeted therapies to determine who responded well and why, so these drugs can be more accurately prescribed.
Dr Hopkins intends to share the study results so that clinicians and breast cancer patients can assess the benefit and risks of these treatments – such as the likelihood of a positive outcome weighed up against the drugs toxicity.
This type of information can help guide treatment decisions that may improve response rates and decrease toxicity to specific therapies, provide an indicator of when to use alternate therapies or focus on palliative care, which may also lengthen the survival of cancer sufferers.
If the success rates of targeted therapies can be improved, they could be included as options in standard care within the next 10 years, helping to successfully treat women with metastatic breast cancer.
Olaparib is known to be effective treatment for breast and ovarian cancers in people with inherited mutations. Many more patients do not have a genetic risk but have cancers arising from spontaneous mutations. Our clinical trial aims to find out whether olaparib benefits patients with breast or ovarian cancers with non-inherited mutations or abnormalities.
Altered metabolism is a key feature of cancer, with metabolic pathways reprogramed to meet the energy demands of cancer cell growth. However, little is known about the role of increased lipid metabolism in breast cancer. We now show that ACC1, a key regulator of lipid metabolism, is expressed by breast tumours, and that inhibiting ACC1 impairs breast cancer progression. This proposal will validate and characterise ACC1 as a novel therapeutic target for the treatment of breast cancer.
Determine the effects of exercise alone +/- systemic therapy on tumour response, metabolic effects, tumour transcriptome and circulating biomarkers in ER+ve and ER-ve PDX models. Determine the effects of exercise on immunological and metabolic responses, cytokines, tumour vascular density and circulating biomarkers in immunocompetent (MMTV-PyMT) mouse tumour models. To determine the feasibility of a graded exercise program in patients with early breast cancer during the administration of adjuvant chemotherapy or ET.
Millions of women with a type of breast cancer fuelled by the female hormone estrogen have benefited from treatments such as tamoxifen and femara, which in most cases successfully prevent breast cancer returning later in life.
However, a third of these hormone-driven breast cancers develop resistance to preventative treatments and the cancer becomes metastatic, spreading throughout the body.
Treatment resistance is the highest cause of mortality in breast cancer. Itâ€™s vitally important to prevent this metastatic stage of breast cancer but as yet there are no effective tests or personalised therapies that can identify or help these women and men.
NBCF-funded Dr Liz Caldon believes that the survival and quality of life would improve significantly if it was possible to predict from the first diagnosed cancer whether it is likely that someone’s cancer will recur, and then treat any recurrence with drugs that are specifically toxic to hormone resistant breast cancer.
But first she is focusing on improving our understanding of hormone resistant breast cancer, specifically the molecular changes that occur as the cancer cells develop resistance, including which genes might be involved.
With this knowledge she and her team will design better predictive tests that detect the presence of resistant cancer cells well before they start to grow as a secondary cancer. They will also determine if these cells have any particular qualities that mean they could be specifically targeted and destroyed during therapy.
Ultimately, this research project aims to eliminate the development of resistance to treatment and stop recurrence from ever happening, providing hope for women and men with hormone resistant breast cancer.
Thanks to medical research itâ€™s now widely recognised that harnessing the immune system is a powerful way to target and kill cancer.
Patients with high levels of immune cells within their tumour respond better to both standard therapies (radiotherapy and chemotherapy) and therapies designed to enhance the immune response against cancer (immunotherapy). However, many patients donâ€™t have immune cells in their tumours so these treatments are not very effective, and more research is needed.
One potential strategy for these patients is the use of white blood cells which are genetically engineered to eradicate cancer cells. These cells, called ‘chimeric antigen receptor T cells’ (CAR T cells), are very effective in blood cancers but donâ€™t work well in other cancers including breast cancer.
One reason for this is because cancer produces adenosine, a substance which has a powerful ability to suppress the immune system. It creates an environment designed to switch off immune cells, giving the cancer plenty of opportunity to grow unchecked.
In a four-year NBCF-funded study, Dr Paul Beavis aims to reprogram the CAR T cells to block the effects of adenosine, so the immune system can recognise, find and destroy any cancer in the body.
The adenosine pathway is most relevant in triple negative breast cancer which is the most aggressive and hardest to treat subtype. Development of a successful immunotherapy would be a significant breakthrough and would have a huge impact on the lives of women diagnosed the disease, and particularly for those with triple negative breast cancer.
Of the more than 16,000 Australian women diagnosed with breast cancer each year about 15 per cent, 2400 women, have a sub-type of the disease called triple negative breast cancer.
Women with triple-negative breast cancer have less treatment options and poor outcomes compared to women with other type of breast cancer, so there is an urgent need to improve treatment methods.
Chemotherapy is a component of treatment for many types of breast cancer, but it is the only effective treatment for triple negative breast cancer. It is a powerful tool; however it has undesirable side effects and can become less effective over time if tumours develop resistance, causing patients to relapse even if their initial treatment was effective.
Many chemotherapy drugs work by damaging the DNA of the cancerâ€™s cells. Some tumours can reverse the effect of the treatment by repairing the damage and continuing to divide and grow.
A promising approach to treating drug resistance is to prevent the cancer cells from repairing the damage caused by the drug. Professor Rob Baxter and his team have discovered a previously unknown way in which triple-negative breast cancer cells can repair DNA that has been damaged by chemotherapy.
The aim of this project is to learn more about this process and discover how to prevent it. Ultimately, the aim is to develop a new treatment that would allow chemotherapy to work more effectively, improving survival for many women with triple negative breast cancer.
Early detection increases the likelihood of breast cancer survival. While population-based breast screening provides the best chance of early detection, it doesnâ€™t provide all women the same level of detection.
Unbeknownst to many women, the density of their breast tissue can impact on the ability of the mammogram to detect tumours. Dense breast tissue is coming to light as one of the strongest predictors of breast cancer risk â€“ on par with carrying a mutation in the BRCA1 and BRCA2 genes.
On a mammogram, the white sections indicate dense breast tissue. Tumours also show up as white and can be obscured if a woman has dense breast tissue. If the mammogram is unable to distinguish a cancerous tissue from healthy dense tissue, tumours can go undetected.
It is becoming increasing clear that women need to be told about their breast density, both because of the impact of dense breast tissue on the effectiveness of a mammogram in finding cancer and because of the increased risk of breast cancer arising from high density.
Measuring breast density is on the cusp of becoming a useful health tool for women, however, more information is needed before it can be incorporated into public health programs.
In conjunction with BreastScreen WA, one of the only state-funded screening programs which informs women of their breast density, Dr Jennifer Stone aims to find out what women do with this information. She will survey women who receive the information about breast density and those that do not, to quantify perceptions, intentions and post-screening behaviour.
This study will be the largest and most comprehensive investigation thus far of the impact of informing screening participants that they have dense breasts and will provide the basis for BreastScreen programs to report measures of breast density to participants in future.
Dr Stone will also investigate the prevalence of dense breast tissue in specific populations, including Aboriginal women (for whom no information currently exists) and younger women (an established risk factor), to help inform public health improvements for these women.
Triple negative breast cancer is more aggressive than other breast cancer subtypes and is more likely to spread to other parts of the body faster. It is also the most difficult type of breast cancer to treat.
Once the cancer spreads â€“ a process called metastasis â€“ the survival outlook falls dramatically, but at present, doctors have no way to predict which patientsâ€™ breast cancer will metastasise.
Many triple negative breast cancers have high levels of two particular proteins which are known to promote the spread of cancer cells. This NBCF-funded study aims to determine if extremely high levels of these proteins can be used to identify the patients whose disease is more likely to spread.
A second focus of the study is to test a new strategy for treating triple negative breast cancer. Unlike other subtypes of breast cancer, there are no therapies specifically tailored for triple negative. Chemotherapy is the only treatment option and it is not very effective once the cancer has spread.
Dr Normand Pouliot aims to see if standard treatments that are being successfully used for other types of breast cancer (such as tamoxifen) can be made to work against triple negative as well.
He will test if blocking the two proteins found in triple negative with novel inhibitors, allows standard treatments to work and stop the growth of the cancer cells.
The combined approach of this project could point to early indicators and more effective treatment of patients with aggressive triple negative breast cancer â€“ two potential breakthroughs that could save the lives of many women in future.